Novartis Grabs Attention for its Development Pipeline

R&D Investor Update focused on potential blockbusters and next-gen therapies.

Novartis has placed significant emphasis on expanding its pipeline of drug candidates, investing heavily in its Innovation Medicines Division. In a recent R&D Update, the company indicated that these efforts have proven favorable.

The company intends to introduce new drugs that have the potential to change the standard of care in diseases with significant negative impacts on patients, including multiple sclerosis (Mayzent, Siponimod; OMB157, ofatumumab); moderate to severe asthma (the oral biologic QAW039, fevipiprant); sickle cell disease (SEG101, crizanlizumab); and lung cancer (ACZ885, canikinumab).

Novartis is also developing numerous next-generation cell, gene and radioligand therapy platforms, with 13 medicines in clinical development and 9 more expected to enter the clinic in 2019.

The company is also looking to expand the approved indications for existing products such as Cosentyx, Entresto and Gilenya by building out their data profiles.

  

David Alvaro, Ph.D.

David is Scientific Editorial Director for That’s Nice and the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University and a Ph.D. in Genetics and Development from Columbia University.